A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by stimulating the mother’s body’s defences to generate defence proteins, which are then passed to the developing baby through the placenta. This maternal immunity provides newborns with immediate protection from the point of delivery, exactly when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence indicating that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst observing that protection can still occur even if administered later in the third trimester.
- Nearly 85% coverage when vaccinated 4 weeks before birth
- Maternal antibodies passed through the placenta protect newborns from day one
- Protection possible with two-week gap before early delivery
- Vaccination during the third trimester still offers meaningful protection for infants
Persuasive evidence from the latest research
The effectiveness of the pregnancy RSV vaccine has been established through a thorough investigation undertaken in England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that half-year window, providing robust and representative data of the vaccine’s real-world impact. The study’s conclusions have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their most vulnerable early months. The scale of this research gives healthcare professionals and expectant parents with confidence in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results reveal a striking picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV during the study period, with the vast majority being infants whose mothers did not receive the vaccination. This stark contrast emphasises the vaccine’s essential role in protecting against serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.
Methodology and scope of study
The research examined birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospitalisations. The substantial sample size and comprehensive nature of the data collection ensured that findings were statistically significant and representative of the broader population, rather than individual cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for maximum protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology measured actual clinical results rather than laboratory-based settings, providing practical evidence of how the vaccine functions when delivered across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and its risks
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection triggers inflammation deep within the lungs and airways, making it extremely challenging for infected babies to feed and breathe effectively. Parents frequently observe their babies struggling visibly, their chests rising whilst they try to pull adequate oxygen into their damaged lungs. Whilst most infants improve through supportive care, a modest yet notable number die from respiratory syncytial virus complications each year, making immunisation programmes a essential public health imperative for defending the youngest and most vulnerable people in our communities.
- RSV triggers lung inflammation, resulting in serious respiratory problems in infants
- Approximately half of infants catch the virus in their first few months of life
- Symptoms span from minor cold-like symptoms to life-threatening chest infections needing hospital treatment
- Over 20,000 UK babies need serious hospital treatment for RSV each year
- Few babies succumb to RSV complications annually in the UK
Uptake rates and expert recommendations
Since the RSV vaccine programme commenced in 2024, health officials have emphasised the significance of pregnant women getting their jab at the best time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that timing matters greatly for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery delivers nearly 85% protection, experts encourage women to get their vaccine as early as possible from 28 weeks of pregnancy forward to maximise the antibodies passed to their babies through the placenta.
The communication from health authorities stays clear: pregnant women should make a priority of getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to pregnant women that protection is still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This flexible approach acknowledges the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.
Regional disparities in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others remain focused to increase awareness and access to the jab. These geographical variations reflect variations in medical facilities, communication strategies, and community involvement initiatives, though the national data shows consistently strong protection regardless of geographical location.
- NHS trusts launching multiple messaging strategies to reach pregnant women
- Inconsistencies across regions in immunisation take-up throughout England require targeted improvement
- Regional health providers modifying schemes to meet community needs and circumstances
Practical implications and parent viewpoints
The vaccine’s impressive effectiveness provides tangible benefits for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the introduction of this protective measure, the 80% decrease in admissions equates to thousands of infants spared from critical disease. Parents no longer face the troubling prospect of watching their newborns gasping for air or struggle to eat, symptoms that characterise serious RSV disease. The vaccine has substantially transformed the terrain of neonatal breathing health, offering expectant mothers a proactive tool to safeguard their most at-risk babies during those vital initial period.
For families like that of Malachi, whose severe RSV infection led to severe brain damage, the vaccine’s availability carries profound emotional significance. His mother’s support of the jab underscores the transformative consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to pregnant women during their final trimester, changing what was once an predictable seasonal threat into a manageable risk.